With the funding, the company was able to establish laboratory infrastructure in the Life Science Factory in Göttingen, hire its first scientific staff, and validate key technologies for the planned platform. This laid the foundation for preparing initial pilot studies with partners from the pharmaceutical and biotech industries and paved the way for market entry. The support was therefore a crucial step in bridging the gap between company founding and operational business, bringing myotwin’s technology into application within a professional laboratory environment.
The myotwin team would like to thank all involved for their support, especially the State of Lower Saxony, NBank, the project sponsor, and the Life Science Valley in Göttingen for their close collaboration throughout the project.
With the successful completion of the HTI program, myotwin not only strengthens its own growth base but also contributes to the biotech hub Göttingen. The company is now ready to enter the next development phase and apply its technologies in further collaborations and studies.
About myotwin
myotwin is a biotech company specializing in human–relevant, preclinical testing systems for the development of cardiovascular drugs. With its proprietary myoScreen platform, myotwin enables the simultaneous measurement of contraction force, tissue stiffness, calcium dynamics, and electrical activity—directly on human heart tissue.
As a next step, myotwin is developing myoAI, a digital twin of the heart muscle that uses artificial intelligence to predict the efficacy and toxicity of drugs. This is giving rise to a new generation of precise, data-driven drug development.
The Germany-based company works closely with research institutions, industry partners, and investors to advance innovative therapies for cardiovascular diseases more quickly and in a more targeted manner. For more information, visit www.myotwin.com.
Forward–looking statements
This communication may contain forward–looking statements based on current assumptions and forecasts made by myotwin’s management. Various known and unknown risks, uncertainties, and other factors could cause the actual results, financial position, development, or performance of the company to differ materially from the estimates given here. These factors include those described in myotwin’s public reports, which are available on the myotwin website at www.myotwin.com. The company assumes no obligation to update such forward-looking statements or to adapt them to future events or developments.
